ASCO 2023: Key Melanoma Studies

CME

Key Studies in Skin Cancer: Independent Conference Coverage of the 2023 ASCO Annual Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 21, 2023

Expiration: August 20, 2024

Jason Luke
Jason Luke, MD, FACP
Jeffrey S. Weber
Jeffrey S. Weber, MD, PhD

Activity

Progress
1
Course Completed

References

  1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472-492.
  2. Egger ME, Bhutiani N, Farmer RW, et al. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes. Surgery. 2016;159:1412-1421.
  3. Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab vs placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399:1718-1729.
  4. Luke JJ, Ascierto PA, Khattak MA, et al. Pembrolizumab vs placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract LBA9505.
  5. Long GV, Luke JJ, Khattak MA, et al. Pembrolizumab vs placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022;23:1378-1388.
  6. Burris HA, Patel MR, Cho DC, et al. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors. Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2019. Abstract 2523.
  7. Khattak A, Weber JS, Meniawy T, et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. LBA9503.
  8. Khattak A, Carlino M, Meniawy T, et al. A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab vs pembrolizumab in patients with resected high-risk melanoma: efficacy and safety results from the randomized, open-label phase 2 mRNA-4157-P201/Keynote-942 trial. Presented at: 2023 American Association for Cancer Research Annual Meeting; April 15-19, 2023. Abstract CT001.
  9. Long GV, Kirkwood JMM, Hoeller C, et al. Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K). Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 9504.
  10. Long GV, Del Vecchio M, Weber J, et al. Adjuvant therapy with nivolumab vs placebo in patients with stage IIB/C melanoma (CheckMate 76K). Presented at: 2022 Society for Melanoma Research International Congress; October 17-20, 2022. LBA.
  11. Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27:301-309.
  12. Reijers ILM, Menzies AM, Versluis JM, et al. The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: three-year data of PRADO and OpACIN-neo. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 101.
  13. Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol. 2023;34:420-430.
  14. Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28:1178-1188.
  15. Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813-823.
  16. Lucas MW, Lijnsvelt J, Pulleman S, et al. The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract TPS9605.
  17. Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab vs nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24-34.
  18. Long GV, Hodi FS, Lipson EJ, et al. Overall survival and response with nivolumab and relatlimab in advanced melanoma. NEJM Evid. 2023;2.
  19. Cemiplimab-rwlc [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2023.
  20. Hamid O, Lewis KD, Weise AM, et al. Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: post adjuvant PD-1 analysis. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 9501.
  21. Mehmi I, Lewis KD, Weise AM, et al. A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: poor-prognosis subgroup analysis. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 9548.
  22. Hamid O, Weise A, Kim TM, et al. Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel). Presented at: 2022 European Society for Medical Oncology Congress; September 9-13, 2022. Abstract 790MO.
  23. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone vs ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40:127-137.
  24. Nivolumab and relatlimab-rmbw [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  25. Tawbi HA, Hodi FS, Lipson EJ, et al. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 9502.
  26. Hodi FS, Chiarion-Sileni V, Lewis KD, et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 9522.